‘Fitness ka jugaad nahi hota, boss’: Shaadi.com’s Anupam Mittal says Ozempic won’t solve India’s obesity problem

In a recent post, Shaadi.com’s Anupam Mittal said Ozempic has proved to be a “gold injection” in India because Indians want to be fit without doing the work. The prescription medication primarily used to treat Type 2 Diabetes has become popular in the country for its weight loss function.

Anupam Mittal says Ozempic won't solve India's obesity problem

“It’s already selling in India at ~₹8,800/month - a ₹1,000 cr annual market,” Mittal shared on LinkedIn. 

He said that demand is real and curiosity is massive.

“The real plot twist lands in March ’26, when GLP-1 patents begin to expire,” the Shark Tank India judge remarked.

He reasoned that when every pharma company discovers its inner “weight-loss baba”, the industry could grow 5 times in a few years.

“Cipla looks ready to open the ashram first,” he said jokingly.

The entrepreneur further said, “If Ozempic becomes for fat loss what Eno is for acidity, half of urban India may be on a monthly injection plan, just to look better on Instagram.”

Anupam Mittal admitted that these drugs could be a medical miracle in many cases.

“For obesity, diabetes, and serious metabolic issues, GLP-1s are genuinely life-changing,” he said. “Science deserves full credit.”

But what about ordinary people?

According to him, lifestyle discipline is needed by average Indians. Next, he listed some lifestyle changes that would be more beneficial than drugs:

• processed foods & sugar ❌

• moving most hours of the day🚶🏻

• strength training 3 times a week & 1 HIIT 🏋🏽

• sleeping 8 hours 😴

Mittal said that though shortcuts are seductive, science is powerful.

“But fitness ka jugaad nahi hota, boss. Lifestyle compounds. Discipline protects,” he concluded.

What is Ozempic?

Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine.

It is used -

a. along with diet and exercise to improve blood sugar (glucose) in adults with Type 2 diabetes,

b. to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease.

Also read: ‘Look at the ₹22 lakh crore we send abroad for fuel',' says Nitin Gadkari backing E20 cars (startuppedia.in)